US 11,911,453 B2
RSV RNA vaccines
Giuseppe Ciaramella, Sudbury, MA (US); Kapil Bahl, Medford, MA (US); Amy Espeseth, Chalfont, PA (US); Andrew J. Bett, Lansdale, PA (US); Pedro Cejas, Oreland, PA (US); Lan Zhang, Chalfont, PA (US); and Christine Shaw, Reading, MA (US)
Assigned to ModernaTX, Inc., Cambridge, MA (US)
Appl. No. 16/965,589
Filed by ModernaTX, Inc., Cambridge, MA (US)
PCT Filed Jan. 28, 2019, PCT No. PCT/US2019/015412
§ 371(c)(1), (2) Date Jul. 28, 2020,
PCT Pub. No. WO2019/148101, PCT Pub. Date Aug. 1, 2019.
Claims priority of provisional application 62/623,240, filed on Jan. 29, 2018.
Prior Publication US 2021/0046173 A1, Feb. 18, 2021
Int. Cl. A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 9/0019 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55555 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A respiratory syncytial virus (RSV) messenger ribonucleic acid (mRNA) vaccine composition, comprising:
an mRNA that comprises an open reading frame (ORF) encoding an RSV F protein comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 5, wherein identity defines the percentage of amino acid residues in the RSV F protein that are identical to residues of SEQ ID NO: 5 after introducing any necessary gaps to align the two full-length sequences; and
a lipid nanoparticle comprising 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % sterol, and 0.5-15 mol % PEG-modified lipid.